Morphic Therapeutics is a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases. In 2019, Johnson & Johnson Innovation and Morphic Therapeutics worked together to shape and execute a collaboration between Morphic and Janssen Pharmaceuticals, Inc., that expands the reach of Morphic’s discovery across all known human integrins.
Following a successful initial phase of collaboration, in 2021, Janssen broadened its R&D collaboration with Morphic to initiate work on a third integrin target, including activating antibodies against this new target. The collaboration leverages Janssen's scale and expertise to explore the potential of Morphic’s MInT technology platform and discovery capabilities and aims to offer potentially promising new treatments for patients with chronic conditions.
Morphic Therapeutics was formed with a single focus – to apply our unique insights into integrin biology and realize its tremendous therapeutic potential for the treatment of serious and chronic diseases. Our collaboration with Johnson & Johnson Innovation is enabling us to leverage - and expand into integrin activators - Morphic’s expertise in integrin biology and drug design with an even greater breadth of disease areas where we may provide new treatment options for patients who are suffering from these debilitating diseases.
Bruce N. Rogers, Ph.D.
Chief Scientific Officer, Morphic Therapeutics